Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more
Market Cap & Net Worth: Vivoryon Therapeutics N.V. (0R3M)
Vivoryon Therapeutics N.V. (LSE:0R3M) has a market capitalization of $11.41 Million (€11.11 Million) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #25399 globally and #427 in its home market, demonstrating a -2.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vivoryon Therapeutics N.V.'s stock price €1.35 by its total outstanding shares 8208010 (8.21 Million).
Vivoryon Therapeutics N.V. Market Cap History: 2026 to 2026
Vivoryon Therapeutics N.V.'s market capitalization history from 2026 to 2026. Data shows growth from $11.41 Million to $11.41 Million (0.00% CAGR).
Vivoryon Therapeutics N.V. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vivoryon Therapeutics N.V.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0R3M by Market Capitalization
Companies near Vivoryon Therapeutics N.V. in the global market cap rankings as of March 18, 2026.
Key companies related to Vivoryon Therapeutics N.V. by market ranking:
- Kim Forest Enterprise Co., Ltd. (TW:6645): Ranked #25390 globally with a market cap of $20.40 Million USD ( NT$675.10 Million TWD).
- P.C.S. Machine Group Holding Public Company Limited (BK:PCSGH): Ranked #25391 globally with a market cap of $20.40 Million USD ( ฿707.44 Million THB).
- TOUAX INH. EO 8 (F:TOX): Ranked #25400 globally with a market cap of $20.35 Million USD ( €19.82 Million EUR).
- TeraGo Inc (PINK:TRAGF): Ranked #25401 globally with a market cap of $20.34 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #25390 | Kim Forest Enterprise Co., Ltd. | TW:6645 | $20.40 Million | NT$14.50 |
| #25391 | P.C.S. Machine Group Holding Public Company Limited | BK:PCSGH | $20.40 Million | ฿3.04 |
| #25400 | TOUAX INH. EO 8 | F:TOX | $20.35 Million | €4.26 |
| #25401 | TeraGo Inc | PINK:TRAGF | $20.34 Million | $0.72 |
Vivoryon Therapeutics N.V. Historical Marketcap From 2026 to 2026
Between 2026 and today, Vivoryon Therapeutics N.V.'s market cap moved from $11.41 Million to $ 11.41 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €11.41 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Vivoryon Therapeutics N.V. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.41 Million USD |
| MoneyControl | $11.41 Million USD |
| MarketWatch | $11.41 Million USD |
| marketcap.company | $11.41 Million USD |
| Reuters | $11.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.